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Abstract
Lung cancer is the number one cause of cancer death; however, no specific serum biomarker is
available till date for detection of early lung cancer. Despite good initial response to chemotherapy,
small-cell lung cancer (SCLC) has a poor prognosis. Therefore, it is important to identify molecular
markers that might influence survival and may serve as potential therapeutic targets. The review
aims to summarize the current knowledge of serum biomarkers in SCLC to improve diagnostic
efficiency in the detection of tumor progression in lung cancer. The current knowledge on the
known serum cytokines and tumor biomarkers of SCLC is emphasized. Recent findings in the
search for novel diagnostic and therapeutic molecular markers using the emerging genomic
technology for detecting lung cancer are also described. It is believed that implementing these new
research techniques will facilitate and improve early detection, prognostication and better
treatment of SCLC.
Introduction
Lung cancer is the most common cancer world over. It is
classified into small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC). They occur with a fre-
quency of 20% and 80% respectively [1]. The aggressive
nature of SCLC with frequent and early metastases
accounts for a dismal 5-year survival rate of <5% with cur-
rent standard therapies. Metastases initially occur in the
lymph nodes and thereafter in other organs such as the
lung itself, liver, adrenal glands, brain, bone, and bone
marrow. The antigenic profile of SCLC coincides mainly
with the neuroendocrine cells because of similar origin.
Early detection of SCLC is challenging mainly due to the
lack of adequate serum tumor markers. In spite of aggres-
sive therapy available today, the prognosis of lung cancer
patients is generally very poor. Therefore, the develop-
ment of novel diagnostic techniques to identify lung can-
cer is important to facilitate earlier diagnosis of primary or
recurring cancers leading to more effective treatment and
improved prognosis [2]. Various molecules detectable in
the serum, useful as putative markers of the disease
include chromogranin A (CgA), pro-gastrin releasing pep-
tide (ProGRP) and neuron-specific enolase (NSE; an γ-γ
isoform of the ubiquitous enolase enzyme), cytokeratin
19 marker CYFRA 21-1 etc. The tumor markers demon-
strate great significance in the neuroendocrine differentia-
tion of lung cancer. Chromogranin A (CgA), a 49 kDa
acidic-soluble protein ubiquitously present in neuroendo-
crine tissues, serves as a suitable circulating marker of neo-
plasms of neuroendocrine origin. Release of this secretory
protein in the serum of patients suffering from SCLC has
been reported. The ability of serum CgA to distinguish
neuroendocrine and non-neuroendocrine tumors either
in situ or by serum level titration has also been suggested
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formance of an immunoradiometric assay of CgA in SCLC
and to use it as a method for discrimination from neuron-
specific enolase (NSE), it has been found that CgA assay
shows better diagnostic sensitivity than NSE in SCLC
(61% versus 57%), especially in limited disease. In con-
trast, NSE reflected disease extent more accurately than
CgA. It has also been shown that the CgA assay is not
affected by hemolysis whereas NSE serum levels greatly
increased in hemolysed sera. CgA assaying by this method
is a reliable procedure in the diagnosis of SCLC whereas,
NSE is suitable marker of choice in staging and monitor-
ing of the disease [3,4].
Recent reports show the expression of selected neuroen-
docrine markers (CgA, NSE and synaptophysin) confirm-
ing the neuroendocrine origin of SCLC and also found the
content of two anti-neoplastic cytokines, IL-2 and IL-12 in
the tumors [5]. Data on the lowered secretion of the two
cytokines, IL-2 and of IL-12 at the time of diagnosis may
represent a prognostic factor for survival in SCLC [5].
Gastrin-releasing peptide (GRP), a gut hormone, is
present in the nerve fibres, brain and neuroendocrine cells
in the fetal lung [6,7]. It was originally isolated from the
porcine stomach and is the mammalian counterpart of
bombesin. In spite of the elevated levels of plasma GRP in
the patients suffering from SCLC, its regular use as a diag-
nostic marker is not preferred because of its unstable
nature in the serum [3].
Various studies have shown that ProGRP is superior to
other markers in its ability to differentiate SCLC and
NSCLC. ProGRP fragment (31–98) is referred to as a com-
mon region to three types of cloned human ProGRP mol-
ecules [7-9]. Serum proGRP (31–98) levels, measured by
ELISA, and the expression of proGRP as well as GRPR
mRNA in SCLC tumor tissues, investigated by reverse tran-
scription-nested polymerase chain reaction (RT-PCR)
amplification, in the individuals with SCLC have been
reported [10]. Expression of RT-PCR based amplification
of transcripts in cancer but not in normal non-neoplastic
cells suggests its use for the sensitive detection of rare dis-
seminated or exfoliated cancer cells to improve cancer
staging and early detection. RT-PCR assays for seven neu-
roendocrine marker transcripts including neural cell
adhesion molecule (NCAM), protein gene product (PGP
9.5), gastrin, gastrin receptor, synaptophysin, preprogas-
trin-releasing peptide (preproGRP) and GRP-receptor for
the detection of rare exfoliated tumor cells in peripheral
venous blood and sputum samples from patients with
lung cancer are reported. Amplification of preproGRP
transcripts from clinical samples indicates this as a sensi-
tive and specific assay to detect disseminated or exfoliated
lung cancer cells either in peripheral blood or sputum
samples [11].
Differential immunization for antigen and 
antibody discovery technology (DIAAD)
Another very recent approach towards the development of
SCLC specific marker is through the antigenic subtraction
of neuroblastoma cells. Multiple attempts to generate
monoclonal antibodies (MoAbs) against SCLC-specific
antigens have failed due to their cross-reactivity with neu-
roendocrine tissues or normal immune cells.
The concept of DIAAD helps to generate immune
response that can be effectively focused on cancer cells.
DIAAD follows protocol of induction of tolerance and
immunity, conducted in sequential manner to "biologi-
cally subtract" the immune response of dominant anti-
gens expressed on the normal cells. This biological
subtraction is gained by first eliminating the immune
response to the normal healthy cells followed by immuni-
zation with the diseased cells [12]. This protocol followed
in the laboratory animals directs the immune response
specifically towards the antigens expressed in the target
and not in the normal cells. Enormous efforts have been
made to generate SCLC-specific MoAbs. The DIAAD
method allows getting rid of B-cells carrying receptors
directed against undesired molecules present on the nor-
mal cells prior to the generation of B-cells specific to the
target cells [12]. Recently, Kruger et al have been able to
generate four MoAbs that can recognize tumor-associated
antigens expressed on SCLC cells. The antibodies do not
cross-react with most of the other undesired cancer cells as
well as normal cells. Moreover, the SCLC antigen is
present in the sera of patients in a concentration that
exceeds 6 logs in comparison with the normal sera, sug-
gesting its role as a secretory marker for the early detection
of the disease. The DIAAD technology is able to generate
antibodies that detect antigens with broad chemical diver-
sity and supports the utility of these antibodies for the
treatment of patients with SCLC as well as in the diagnosis
of the disease.
DNA markers
Another major focus in the generation of a sensitive and
tumor specific marker in the lung cancer patients is the
plasma DNA. The accumulation of genetic alterations is
seen very commonly in lung cancers. Amongst microsatel-
lite (MS) alterations, primary lung cancer seldom shows
microsatellite instability but more often is depicted by fre-
quent loss of heterozygosity. The levels of free-circulating
DNA in the plasma are known to be higher in patients
than in healthy controls. Plasma DNA analysis is sug-
gested to be of significance for the prognosis of the dis-
ease. Attempts have been made to study and evaluate the
sensitivity and specificity of the large group of microsatel-Page 2 of 5
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the plasma and paired tumor DNA of lung cancer
patients. The method is useful for monitoring lung cancer
progression at different stages of the disease [13].
Reports by Chen et al and Gonzalez et al show the best sen-
sitivity for characterizing plasma DNA in SCLC at 71%
using three molecular markers (ACTBP2, UT762 and AR).
The sensitivity in other studies ranged from 23–50% in
both SCLC and NSCLC using the same markers as alone
or 4–5 markers targeting mainly chromosome arm 3p
[14,15].
Small-cell lung cancer (SCLC) cells express various mark-
ers of neuronal differentiation associated with deficient
activity of the neuron-restricted silencer factor (NRSF).
The glycine receptor (GlyR) alpha1 subunit gene, GLRA1,
contains a sequence motif for NRSF binding (NRSE)
within its 5' UTR, which serves as a cellular surrogate
marker for NRSF activity. Expression of GLRA1 in non
transformed cells is largely restricted to cells in the spinal
cord, retina and brain stem. NRSF-mediated suppression
of an expression construct harboring the NRSE of the
GLRA1 (GLRA1 NRSE) gene has been shown to be
impaired in three of four 'classic' SCLC cell lines, whereas
exogenous overexpression of NRSF in NRSF-deficient
SCLC cell lines has been reported to reconstitute the
silencing of the reporter plasmid [16]. Most interestingly,
induction of apoptosis in SCLC cells is reported upon
reconstitution of NRSF expression, indicating inhibition
of NRSF activity as a crucial step in the carcinogenesis of a
subgroup of SCLC [16].
The human achaete-scute homologue 1 (HASH1, ASCL1),
a lineage-specific basic helix-loop-helix member of the
achaete-scute family, is essential for the generation of pul-
monary neuroendocrine (NE) cells during lung develop-
ment. In small cell lung cancer (SCLC), the gene is highly
expressed and the expression of HASH1 correlates with
NE features found in SCLCs. A highly sensitive reverse
transcription-PCR method for quantifying HASH1 mRNA
in clinical samples, using real-time fluorescence reso-
nance energy transfer technology has shown marked and
measurable differences existing between SCLCs and other
lung tissues (either NSCLC or normal bronchus). This
method contributes to diagnosis based on molecular pro-
filing of tumors using HASH1, ASCL1 as a marker for
SCLC [17].
Role of kinases
Receptor tyrosine kinases (RTKs) initiate specific intercel-
lular signaling pathways in response to binding of extra-
cellular growth factors and are known to play an
important role in regulating normal and cancer cell
growth and differentiation. Overexpression of receptor
type tyrosine kinase is associated with an aggressive tumor
phenotype and poor outcome of various cancers. A tyro-
sine kinase, c-kit (CD117) oncoprotein is expressed in a
variety of tumors including mastocytosis, germ cell
tumors, gastrointestinal stromal tumors (GIST) and
SCLC. Various analyses have consistently shown that all
SCLCs express abundant stem cell factor (SCF) mRNA,
and since SCF is the c-kit ligand, it suggests the possible
involvement of an autocrine mechanism in the develop-
ment of c-kit positive SCLCs [18] and LCNECs (large cell
neuroendocrine carcinoma) [19]. Reports that over 70%
of SCLC cell lines and tumor co-express c-kit and its lig-
and, SCF suggest that they are part of autocrine loop in
these cells [19-21]. SCF appears to be an important
growth factor for SCLC cells, because growth suppression
has been observed when a kinase defective c-kit was intro-
duced into a c-kit/SCF expressing cell line [22]. Cell lines
expressing the c-kit gene are also shown to express either
the L- and N-myc genes, however, those cell lines that
express the c-myc gene do not express the c-kit gene. Het-
erologous expression of c-myc correlates with a marked
down-regulation of c-kit expression in several small lung
cancer cell lines when transfected with a c-myc expression
vector. Regulation of c-kit expression by the myc gene
family may be partly responsible for the differing biologi-
cal properties of cell lines and tumors which express N-
and L-myc versus those that express c-myc [20]. STI571 is
a small synthetic molecule that shows selective inhibition
of tyrosine kinase activity and function through competi-
tive inhibition of ATP binding of the enzymes since most
of the SCLC expresses c-kit tyrosine kinase oncoprotein,
STI571 might be a potential therapeutic agent in the treat-
ment of SCLC [23]. RTKs are a target for novel therapies
currently being investigated.
Epidermal growth factor receptor (EGFR) inhibitors and
c-Kit inhibitors and c-Met inhibitors are being used. Even
though the RTK inhibitors provide a novel mechanism, it
is important to realize that lung cancer etiology is a com-
plex process, and eventually standard chemotherapy may
need to be used in conjunction with these novel therapies
to make an important difference in response rates. The
levels of carcinoembryonic antigen (CEA) and the activi-
ties of creatine kinase isoenzyme BB (CK-BB) in lung can-
cers have been reported in the literature. Increased levels
of CEA are observed mostly in patients with NSCLC, while
enhanced activities of CK-BB in patients with SCLC. A
relationship between enhanced levels of CEA or CK-BB
and advanced carcinoma has also been demonstrated. The
increased values of studied markers seem to indicate the
limited possibility of surgical treatment and they are also
important in prognosis after the resection of lung tissue
[24].Page 3 of 5
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Telomerase is an enzyme that adds hexameric TTAGGG
nucleotide repeats onto the ends of vertebrate chromo-
somal DNAs (i.e., telomeres) to compensate for losses
that occur with each round of DNA replication. It has
been suggested that immortalized cells (including some,
but probably not all, cancer cells) continue to proliferate
indefinitely because they express telomerase. Cancers that
exhibit high levels of telomerase activity, such as all of the
small-cell lung cancers are likely to consist mainly of
immortal cells. Telomerase activity may be useful both as
a diagnostic marker to detect the existence of immortal
lung cancer cells in clinical materials and as a target for
therapeutic intervention [25].
Significance of apoptotic cell death pathway
Clonal expression and tumor growth results not only
from the acceleration of intrinsic proliferation but also
due to escape from apoptotic cell death. Alterations in the
normal physiological apoptotic pathway results in a sig-
nificant survival advantage of the tumor cells even in the
unfavorable conditions. The role of Fas cell death receptor
pathway is well established in the inhibition of apoptosis.
FasR (a member of tumor necrosis factor superfamily)
interacts with FasL to trigger cells to undergo apoptosis.
Evidences suggest that the Fas expression is clearly
decreased in lung tumor, regardless of the histological
type, with clear over expression of FasL in the high grade
SCLC tumors [26].
Hopkins-Donaldson et al have demonstrated the resist-
ance of small cell lung cancer cell lines to FasL and TRAIL-
induced apoptosis, which could be explained by an
absence of Fas and TRAIL-R1 mRNA expression and a defi-
ciency of surface TRAIL-R2 protein [27]. Reduced levels of
Fas, TRAIL-R1 and caspase-8 mRNA molecules in SCLC
tumors compared to NSCLC tumors justify the resistance
of SCLC cells to apoptosis mediated by death receptors.
RT-PCR studies on loss of expression of caspase-8 in most
of SCLC cell lines but with retained expression in all 22
non-SCLC (NSCLC) lines tested have been reported.
Recent reports indicate that caspase-8 expression is lost via
a combination of promoter methylation and allelic loss in
a subset of neuroblastomas [28].
SCLC is surrounded by an extensive stroma of extracellu-
lar matrix (ECM) at both primary and metastatic sites.
Adhesion of SCLC cells to matrix enhances tumorigenicity
and confers resistance to chemotherapeutic agents as a
result of beta1 integrin-stimulated tyrosine kinase activa-
tion, suppressing chemotherapy-induced apoptosis. SCLC
may create a specialized microenvironment, and the sur-
vival of cells bound to ECM could explain the partial
responses and local recurrence of SCLC often seen clini-
cally after chemotherapy. Strategies based on blocking
beta1 integrin-mediated survival signals may represent a
new therapeutic approach to improve the response to
chemotherapy in SCLC [29].
Conclusions
In conclusion, availability of tumor markers such as
serum CgA, GRP and proGRP as determinants of disease
in SCLC may improve the overall outlook. DIAAD's
capacity to elicit a robust response to broad range of non-
dominant cancer antigens uniquely expressed on SCLC
allows generation of specific MoAbs against SCLC anti-
gens. These specific MoAbs may serve as a crucial biomar-
ker for early diagnosis of the disease, as well as for the
therapeutic intervention for SCLC. Presently, the diagno-
sis of SCLC is made at an advanced stage with a dismal
outlook, however, its early detection may promise a cure.
Thus, the addition of an early new diagnostic test for SCLC
will indisputably save many lives and also help in the pro-
longed survival of patients suffering from this devastating
disease.
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